Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Core Scientific (CORZW) EBT (2020 - 2025)

Core Scientific (CORZW) has disclosed EBT for 6 consecutive years, with $216.1 million as the latest value for Q4 2025.

  • Quarterly EBT rose 174.3% to $216.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$288.0 million through Dec 2025, up 79.96% year-over-year, with the annual reading at -$288.0 million for FY2025, 79.96% up from the prior year.
  • EBT hit $216.1 million in Q4 2025 for Core Scientific, up from -$143.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $576.5 million in Q1 2025 to a low of -$936.6 million in Q2 2025.
  • Historically, EBT has averaged -$203.6 million across 5 years, with a median of -$92.5 million in 2023.
  • Biggest five-year swings in EBT: surged 740157.69% in 2021 and later plummeted 25965.69% in 2022.
  • Year by year, EBT stood at $77.0 million in 2021, then plummeted by 692.91% to -$456.3 million in 2022, then soared by 57.19% to -$195.4 million in 2023, then tumbled by 48.84% to -$290.8 million in 2024, then soared by 174.3% to $216.1 million in 2025.
  • Business Quant data shows EBT for CORZW at $216.1 million in Q4 2025, -$143.9 million in Q3 2025, and -$936.6 million in Q2 2025.